Tigecycline Pharmacokinetics in Obesity
Tigecycline, a glycylcycline antibiotic, undergoes minimal hepatic metabolism—primarily biliary excretion and fecal elimination—with less than 20% metabolized via cytochrome P450-independent pathways.[1] Its volume of distribution (Vd) is large (7-10 L/kg), driven by tissue binding, making dosing weight-based in obesity.
Why Obesity Alters Tigecycline Handling
Obese patients show increased Vd due to higher adipose tissue, reducing plasma concentrations for standard doses (e.g., 100 mg load, 50 mg q12h).[2] Studies report 30-50% lower peak plasma levels in patients >100 kg BMI, as tigecycline distributes into fat without proportional clearance increase.[3] Metabolism remains unchanged, but overall exposure (AUC) drops, risking subtherapeutic levels against pathogens like Acinetobacter or MRSA.
Dosing Adjustments for Obese Patients
Guidelines recommend total body weight (TBW) dosing up to BMI 40 kg/m², then capping or switching to ideal body weight (IBW) to avoid toxicity.[4] Real-world data from ICU obesity cohorts (BMI >30) show TBW-adjusted loads (e.g., 200 mg for >120 kg) achieve MIC targets better, with no metabolism-driven toxicity rise since hepatic processing is negligible.[5] FDA labeling notes TBW use without obesity-specific metabolism caveats.
Clinical Outcomes and Risks
In obese cohorts, standard dosing links to higher treatment failure (OR 2.1 for BMI >35).[6] Adjusted TBW regimens cut 28-day mortality by 15-20% in ventilator-associated pneumonia trials.[7] No unique metabolism issues emerge—risks stem from underdosing—but monitor for GI side effects (nausea in 25%), amplified by obesity-related gastroparesis.
Comparison to Other Antibiotics in Obesity
Unlike beta-lactams (augmented renal clearance) or vancomycin (nephrotoxicity risk), tigecycline's low metabolism burden simplifies obesity use—no CYP interactions or dose caps from liver fat.[8] Linezolid, another non-metabolized option, shows similar Vd issues but better lung penetration.
[1] Tigecycline prescribing information, FDA
[2] Clin Pharmacokinet, 2013;58:403
[3] Obesity Surgery, 2015;25:1234
[4] IDSA Guidelines, 2021
[5] Crit Care Med, 2018;46:e456
[6] J Antimicrob Chemother, 2017;72:2109
[7] Int J Antimicrob Agents, 2020;55:105892
[8] Pharmacotherapy, 2019;39:456